KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CareDx (CDNA) Shares Outstanding (Diluted Average) (2016 - 2026)

CareDx's Shares Outstanding (Diluted Average) history spans 11 years, with the latest figure at $53.1 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) fell 3.86% to $53.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $53.1 million, a 3.86% decrease, with the full-year FY2025 number at $53.3 million, down 5.89% from a year prior.
  • Shares Outstanding (Diluted Average) hit $53.1 million in Q1 2026 for CareDx, roughly flat from $53.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for CDNA hit a ceiling of $56.6 million in Q4 2024 and a floor of $51.7 million in Q1 2024.
  • Historically, Shares Outstanding (Diluted Average) has averaged $53.6 million across 5 years, with a median of $53.3 million in 2022.
  • The widest YoY moves for Shares Outstanding (Diluted Average): up 6.91% in 2025, down 5.89% in 2025.
  • Tracing CDNA's Shares Outstanding (Diluted Average) over 5 years: stood at $53.3 million in 2022, then rose by 0.83% to $53.8 million in 2023, then rose by 5.31% to $56.6 million in 2024, then dropped by 5.89% to $53.3 million in 2025, then fell by 0.3% to $53.1 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CDNA at $53.1 million in Q1 2026, $53.3 million in Q4 2025, and $53.7 million in Q3 2025.